Member Info for LiveLongnProsper

Question is what does DWP710 do, and does it involve Affimers? If this was really about mesenchymal stem cells modified to create Affimers in the body, that would be truly massive. Have to say that I doubt it is us, hope I'm wrong.
GLA

Update on post from @Richob on 12/12/2020.
https://clinicaltrials.gov/ct2/show/study/NCT04535856
Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients (DW-MSC).
Being carried out in Indonesia. Completed Jan 14th, record updated Jan 25th.
Not clear if these mesenchymal stem cells have been ‘genetically modified to produce and secrete therapeutic Affimer proteins in situ in the patient’ – as per the AffyXell research.
Anyone any deeper insight?
GLA

November 23rd LFT ‘holding’ statement.
January 6th Bruker take a stake in Adeptrix.
January 28th Avacta collaboration agreement with Bruker.
BAMS works and we will soon have the “definitive clinical performance data."
(Also, seems likely Affimers will be used to detect other viruses using BAMS assays).
21st January FT article regarding PA Consulting contract “to find suitable British manufacturers of lateral flow devices (LFDs), which provide results in under 30 minutes, and scale up manufacturing to reach 2m tests a day by April 2021.”
29th January a few more tests ordered from Innova to last through to mid-Feb when the new contract award deliveries commence.
In the meantime, as noted by @xyz, @Energyshares et al, Avacta are …
In the (surely) more capable hands of FTI Consulting (at least should be more capable than ‘pink pyjamas’ or whatever).
Re-assigning staff to ‘Operations’.
Hiring new staff.
Through their University and other collaborators ‘cracking on’ with Affimer research.
Progressing the AVA6000 CTA.
Licensing out pre|CISIONTM FAP sensitive activation platform for radiopharmaceuticals to POINT Biopharma, and Affimers to Astrea Bioseparations.
Growing their partnerships with Daewoong and LG Chem Life Sciences.
This is going to come to a head soon, and it will be big, that’s BIG.
(IMHO of course).
GLA

On Sophie Ridge just now "we should be using more if these rapid antigen tests" and he is talking to govt ministers.
GLA

Affimer-Based Europium Chelates Allow Sensitive Optical Biosensing in a Range of Human Disease Biomarkers, published on 27/01/21.
“Biosensors offer the prospect of reagent-less, processing-free measurements at the patient’s bedside. Here, we report a platform for biosensing based on chelated Eu3+ against a range of proteins including biomarkers of cardiac injury (human myoglobin), stroke (glial fibrillary acidic protein (GFAP)), inflammation (C-reactive protein (CRP)) and colorectal cancer (carcinoembryonic antigen (CEA)). The Eu3+ ions are chelated by modified synthetic binding proteins (Affimers), which offer an alternative targeting strategy to existing antibodies.”
Worth checking on the source of funding for this research – and I don’t mean Leeds University, just shows who knows about Affimers!
https://www.mdpi.com/1424-8220/21/3/831/pdf
Interesting as still embargoed on Leeds site …
http://etheses.whiterose.ac.uk/27029/
GLA

Can we have a 'big bada booooom' please.
GLA

Lots of Affimer research, for starters find this site and search on ‘Affimer’ …
https://etheses.whiterose.ac.uk/
The Leeds University Affimer team …
https://dctomlinson.wixsite.com/laboratory
GLA

Pun intended ...
https://twitter.com/SecureProfit/status/1354587467702263808
From SNG board.
Worth being aware that the 'anti-hedge fund' crew are still at work. Encourages irrational behaviour across the market with PI's pulling out to follow the next 'ant-shorter' attack.
Worth recognising what a quality stock we're invested in.
Got to feel sorry for the hedgers/shorters? No, OK with me, haha.
GLA

Positive waves, man. Will soon have fixed the fuel system as well!
GLA

Yes, also noticed the much clearer and deliberate distinction between Diagnostics and Therapeutics - separate divisions, different locations. Surely suggests easily separable, should the opportunity present ...?
GLA

This thread from @BigBiteNow on Twitter warrants very careful reading. The change in language in today's RNS is very encouraging. Much more to come ...
https://twitter.com/BigBiteNow/status/1354710189887393792
GLA

06/08/20!

AffiDX™ on govt. trade mark journal – covers tests and reagents, mobile apps, apparatus and instruments, and services. Registered 06/08/21.
https://www.ipo.gov.uk/t-tmj/tm-journals/2020-037/UK00003519801.html
https://trademarks.ipo.gov.uk/ipo-tmcase/page/Results/1/UK00003519801
AffiDX™ shows as pending as at 29/09/20 on Avacta site.
https://avacta.com/wp-content/uploads/2020/10/Avacta-Ltd-Registered-Trade-Marks-summary-29.09.2020.pdf
GLA

@jdt1990, like the more optimistic hint here, would explain the appointment of FTI Consulting .
GLA

Interesting one Zoom, as bored watching sp go down had a a look at previous RNS's and we've had some kind of update by 25th Jan since 2014 - got bored again at that point. So ...
No regular trading update
No specific LFT or BAMS news for 2 months (and that was only a 'holding position' note)
No leaks (despite the odd attempt to encourage such)
No recent TR1's
No really big trades
Low daily volume of trades
What does it all mean?
(Does look the Therapeutics side of the business moving forward though, and plenty of Affimer research going on)
GLA

Now here’s an interesting thread to sleep on …
https://twitter.com/MylesMcNulty/status/1354170855996194819
Ophidian certain we’re working with Mologic and ours will be ‘the one’. Myles a little less sanguine?
GLA

Think spread was 142/144 at the time, see trades either side, so looks like 2 decent buys to me ...
2021-01-26T09:31:32.893 GBX 142.875 500 714.375 Off-Book AIMX
2021-01-26T09:33:05.613 GBX 143.25 145060 207798.45 Off-Book AIMX LRGS
2021-01-26T09:33:19.583 GBX 144 145000 208800 Off-Book AIMX LRGS
2021-01-26T09:34:03.933 GBX 142.875 700 1000.125 Off-Book AIMX
GLA

There are other LFT manufacturers, for example …
https://www.lateraldx.com/services/contract-lateral-flow-test-manufacture.html
Lateral Dx setup in 2019, have their own Gold Colloid product, but provide contract LFT development and manufacturing. They announced expanded facilities “to accommodate COVID-19 demand” on 18/12/20. They have been linked to a couple of antibody test companies – Coronex and Excivion, but probably not the real focus just now?
So what are these guys doing, what about antigen tests? Anyone have any insight here?
GLA

IP, patent applications, commercial sensitivity, follow-up research being sorted, etc. Many, interesting, reasons.
GLA

Just to bump.
https://avacta.com/about/resources/published-papers/
Published papers from Avacta site.
A few more papers below from White Rose eTheses Online (Leeds University). These have been completed, but are ‘embargoed’. Why – peer group review, review by Avacta, review by other 3rd-parties?
Main point is, a lot of Affimer research going on through The University of Leeds Faculties of Medicine and Health and Biological Sciences, also the Institute for Molecular and Cellular Biology (Leeds).
http://etheses.whiterose.ac.uk/27897/
Characterisation of HER2 binding Affimer drug conjugates in 2D and 3D cell culture. Affimers for HER2 (breast cancer) – 29/11/2020, embargoed until 1/11/2025.
http://etheses.whiterose.ac.uk/16689/
The use of antiplasmin-specific Affimer as a tool to modulate fibrin clot properties and thrombosis risk. Affimers for thrombosis risk – 6/11/2020, embargoed until 1/11/2025.
http://etheses.whiterose.ac.uk/27029/
Developing an Europium-based optical biosensor for detection of protein biomarkers. Affimer – Eu3+ (Europium) complexes for protein biomarker detection of heart attacks, ischemic stroke – 9/6/202, embargoed until 1/7/2023.
http://etheses.whiterose.ac.uk/26760/
Development of Affimer Reagents to Modulate the Enzyme Activity of NDM-1. Affimers against antimicrobial resistance (NDM-1 inhibitor) – 26/6/2020, embargoed until 1/6/2025.
GLA